# A Research Study in Children With a Low Level of Hormone to Grow. Treatment is Somapacitan Once a Week Compared to Norditropin® Once a Day (REAL4)

> **NCT03811535** · PHASE3 · COMPLETED · sponsor: **Novo Nordisk A/S** · enrollment: 200 (actual)

## Conditions studied

- Growth Hormone Deficiency in Children

## Interventions

- **DRUG:** Somapacitan
- **DRUG:** Norditropin®

## Key facts

- **NCT ID:** NCT03811535
- **Lead sponsor:** Novo Nordisk A/S
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-05-20
- **Primary completion:** 2021-11-10
- **Final completion:** 2025-09-30
- **Target enrollment:** 200 (ACTUAL)
- **Last updated:** 2026-01-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03811535

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03811535, "A Research Study in Children With a Low Level of Hormone to Grow. Treatment is Somapacitan Once a Week Compared to Norditropin® Once a Day (REAL4)". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT03811535. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*